{
    "info": {
        "nct_id": "NCT02992522",
        "official_title": "A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",
        "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Prior venetoclax or other BCL-2 family inhibitors or prior lenalidomide is not permitted\n* Creatinine clearance >= 50 ml/min using a 24 hour creatinine clearance or estimated creatinine clearance using the Cockcroft-Gault equation\n* Bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN\n* Absolute neutrophil count (ANC) >= 1000/mm^3\n* Platelet >= 75,000/mm^3\n\n  * Unless related to bone marrow involvement with disease, in which case platelets must be >= 50,000/mm^3\n* Recovery to =< grade 1 from all toxicities associated with prior therapy except alopecia\n* Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) of any of the following subtypes recognized by the World Health Organization (WHO) classification: Burkitt lymphoma, B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, or follicular lymphoma; patients with evidence of histological transformation to diffuse large B-cell lymphoma from indolent NHL are eligible\n* At least one prior therapy; prior autologous stem cell transplant is permitted; patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted\n* Patients with indolent lymphoma must have an indication for treatment in the opinion of the investigator\n* Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease\n* All study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program\n* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program\n* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent)\n* EXPANSION COHORT\n* Cohort A will enroll 10 patients with a diagnosis of diffuse large B-cell lymphoma; B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (double hit lymphoma), Burkitt lymphoma, and transformed lymphoma\n* Cohort B will enroll 20 patients with a diagnosis of follicular lymphoma, grade 1-2 and 3A; grade 3B is excluded; diagnoses made by a fine needle aspirate or bone marrow biopsy alone are not permitted\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with active central nervous system (CNS) involvement with lymphoma are not eligible\n* Patients with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1) are not eligible\n* Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection; patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing\n* Prior allogeneic stem cell transplant is not permitted\n* Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of venetoclax or lenalidomide\n* Any chemotherapy or radiation therapy within 4 weeks of the first dose of study drug\n* Patients may take steroids for disease control up to 24 hours prior to study enrollment\n* Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of venetoclax and lenalidomide, or put the study outcomes at undue risk\n* A cardiovascular disability status of New York Heart Association class >= 2\n* History of severe allergic reactions to humanized monoclonal antibodies\n* History of other malignancy that could affect compliance with the protocol or interpretation of results; patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible; patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded; individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator\n* Known hypersensitivity to any of the study drugs or analogs\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy\n* Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)\n* Received the following agents within 7 days prior to the first dose of venetoclax:\n\n  * Strong and moderate CYP3A inhibitors\n  * Strong and moderate CYP3A inducers\n  * Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax\n* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis\n* Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment\n* Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis\n* Malabsorption syndrome or other condition that precludes enteral route of administration\n* Known allergy to both xanthine oxidase inhibitors and rasburicase\n* Pregnant or lactating, or intending to become pregnant during the study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EXPANSION COHORT",
            "criterions": [
                {
                    "exact_snippets": "EXPANSION COHORT",
                    "criterion": "expansion cohort enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless due to Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet >= 75,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelet >= 75,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program",
            "criterions": [
                {
                    "exact_snippets": "Females of reproductive potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program",
                    "criterion": "adherence to scheduled pregnancy testing",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "testing program",
                            "expected_value": "Revlimid REMS program"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior venetoclax or other BCL-2 family inhibitors or prior lenalidomide is not permitted",
            "criterions": [
                {
                    "exact_snippets": "Prior venetoclax ... is not permitted",
                    "criterion": "prior venetoclax use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other BCL-2 family inhibitors ... is not permitted",
                    "criterion": "prior BCL-2 family inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior lenalidomide is not permitted",
                    "criterion": "prior lenalidomide use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recovery to =< grade 1 from all toxicities associated with prior therapy except alopecia",
            "criterions": [
                {
                    "exact_snippets": "Recovery to =< grade 1 from all toxicities associated with prior therapy except alopecia",
                    "criterion": "toxicities associated with prior therapy (except alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with indolent lymphoma must have an indication for treatment in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Patients with indolent lymphoma",
                    "criterion": "indolent lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have an indication for treatment in the opinion of the investigator",
                    "criterion": "indication for treatment (in indolent lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease",
            "criterions": [
                {
                    "exact_snippets": "Radiographically measurable disease by computed tomography (CT) scan",
                    "criterion": "measurable disease by CT scan",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one node > 1.5 cm in size",
                    "criterion": "lymph node size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "assessable disease",
                    "criterion": "assessable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B will enroll 20 patients with a diagnosis of follicular lymphoma, grade 1-2 and 3A; grade 3B is excluded; diagnoses made by a fine needle aspirate or bone marrow biopsy alone are not permitted",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of follicular lymphoma",
                    "criterion": "follicular lymphoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 1-2 and 3A; grade 3B is excluded",
                    "criterion": "follicular lymphoma grade",
                    "requirements": [
                        {
                            "requirement_type": "allowed_grades",
                            "expected_value": [
                                "1",
                                "2",
                                "3A"
                            ]
                        },
                        {
                            "requirement_type": "excluded_grades",
                            "expected_value": [
                                "3B"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnoses made by a fine needle aspirate or bone marrow biopsy alone are not permitted",
                    "criterion": "diagnosis method",
                    "requirements": [
                        {
                            "requirement_type": "method_exclusion",
                            "expected_value": [
                                "fine needle aspirate alone",
                                "bone marrow biopsy alone"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unless related to bone marrow involvement with disease, in which case platelets must be >= 50,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "platelets must be >= 50,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Unless related to bone marrow involvement with disease",
                    "criterion": "bone marrow involvement with disease",
                    "requirements": [
                        {
                            "requirement_type": "relatedness to low platelets",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... =< 3 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort A will enroll 10 patients with a diagnosis of diffuse large B-cell lymphoma; B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (double hit lymphoma), Burkitt lymphoma, and transformed lymphoma",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of diffuse large B-cell lymphoma",
                    "criterion": "diffuse large B-cell lymphoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of ... B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (double hit lymphoma)",
                    "criterion": "B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (double hit lymphoma) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of ... Burkitt lymphoma",
                    "criterion": "Burkitt lymphoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of ... transformed lymphoma",
                    "criterion": "transformed lymphoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance >= 50 ml/min using a 24 hour creatinine clearance or estimated creatinine clearance using the Cockcroft-Gault equation",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance >= 50 ml/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "using a 24 hour creatinine clearance or estimated creatinine clearance using the Cockcroft-Gault equation",
                    "criterion": "creatinine clearance measurement method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "24 hour creatinine clearance",
                                "estimated creatinine clearance using the Cockcroft-Gault equation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one prior therapy; prior autologous stem cell transplant is permitted; patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted",
            "criterions": [
                {
                    "exact_snippets": "At least one prior therapy",
                    "criterion": "number of prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior autologous stem cell transplant is permitted",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT",
                    "criterion": "eligibility for HDT/ASCT in aggressive lymphoma patients without prior HDT/ASCT",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior allogeneic stem cell transplant is not permitted",
                    "criterion": "prior allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent)",
            "criterions": [
                {
                    "exact_snippets": "Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 81,
                                        "unit": "mg"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 325,
                                        "unit": "mg"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "daily"
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "prophylactic anticoagulation"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent",
                    "criterion": "aspirin intolerance",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent",
                    "criterion": "low molecular weight heparin or equivalent use",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "aspirin intolerance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) of any of the following subtypes recognized by the World Health Organization (WHO) classification: Burkitt lymphoma, B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, or follicular lymphoma; patients with evidence of histological transformation to diffuse large B-cell lymphoma from indolent NHL are eligible",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL)",
                    "criterion": "B-cell non-Hodgkin's lymphoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any of the following subtypes recognized by the World Health Organization (WHO) classification: Burkitt lymphoma, B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, or follicular lymphoma",
                    "criterion": "NHL subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "Burkitt lymphoma",
                                "B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma",
                                "diffuse large B-cell lymphoma",
                                "marginal zone lymphoma",
                                "follicular lymphoma"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with evidence of histological transformation to diffuse large B-cell lymphoma from indolent NHL are eligible",
                    "criterion": "histological transformation to diffuse large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "evidence of transformation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "origin",
                            "expected_value": "indolent NHL"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program",
            "criterions": [
                {
                    "exact_snippets": "registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program",
                    "criterion": "Revlimid REMS program registration",
                    "requirements": [
                        {
                            "requirement_type": "registration_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with the requirements of the REMS program",
                    "criterion": "compliance with REMS program requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with active central nervous system (CNS) involvement with lymphoma are not eligible",
            "criterions": [
                {
                    "exact_snippets": "active central nervous system (CNS) involvement with lymphoma",
                    "criterion": "central nervous system (CNS) involvement with lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell transplant is not permitted",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell transplant is not permitted",
                    "criterion": "prior allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Strong and moderate CYP3A inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Strong and moderate CYP3A inhibitors",
                    "criterion": "CYP3A inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "strength",
                            "expected_value": [
                                "strong",
                                "moderate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)",
            "criterions": [
                {
                    "exact_snippets": "Requires the use of warfarin",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Strong and moderate CYP3A inducers",
            "criterions": [
                {
                    "exact_snippets": "Strong and moderate CYP3A inducers",
                    "criterion": "CYP3A inducers",
                    "requirements": [
                        {
                            "requirement_type": "induction strength",
                            "expected_value": [
                                "strong",
                                "moderate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any of the study drugs or analogs",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any of the study drugs or analogs",
                    "criterion": "hypersensitivity to study drugs or analogs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic reactions to humanized monoclonal antibodies",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic reactions to humanized monoclonal antibodies",
                    "criterion": "allergic reactions to humanized monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating, or intending to become pregnant during the study",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intending to become pregnant during the study",
                    "criterion": "intention to become pregnant during the study",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergy to both xanthine oxidase inhibitors and rasburicase",
            "criterions": [
                {
                    "exact_snippets": "Known allergy to both xanthine oxidase inhibitors and rasburicase",
                    "criterion": "allergy to xanthine oxidase inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergy to both xanthine oxidase inhibitors and rasburicase",
                    "criterion": "allergy to rasburicase",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A cardiovascular disability status of New York Heart Association class >= 2",
            "criterions": [
                {
                    "exact_snippets": "A cardiovascular disability status of New York Heart Association class >= 2",
                    "criterion": "New York Heart Association class",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant history of liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "viral or other hepatitis",
                    "criterion": "hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current alcohol abuse",
                    "criterion": "alcohol abuse",
                    "requirements": [
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malabsorption syndrome or other condition that precludes enteral route of administration",
            "criterions": [
                {
                    "exact_snippets": "Malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other condition that precludes enteral route of administration",
                    "criterion": "condition precluding enteral route of administration",
                    "requirements": [
                        {
                            "requirement_type": "effect on enteral administration",
                            "expected_value": "precludes"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received the following agents within 7 days prior to the first dose of venetoclax:",
            "criterions": [
                {
                    "exact_snippets": "Received the following agents within 7 days prior to the first dose of venetoclax",
                    "criterion": "receipt of specified agents",
                    "requirements": [
                        {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative to event",
                            "expected_value": "prior to the first dose of venetoclax"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may take steroids for disease control up to 24 hours prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Patients may take steroids for disease control up to 24 hours prior to study enrollment",
                    "criterion": "steroid use for disease control",
                    "requirements": [
                        {
                            "requirement_type": "timing before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment",
            "criterions": [
                {
                    "exact_snippets": "Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment",
                    "criterion": "receipt of live-virus vaccines",
                    "requirements": [
                        {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "need for live-virus vaccines at any time during study treatment",
                    "criterion": "need for live-virus vaccines",
                    "requirements": [
                        {
                            "requirement_type": "need during study treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax",
            "criterions": [
                {
                    "exact_snippets": "Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax",
                    "criterion": "consumption of grapefruit, grapefruit products, Seville oranges, Seville orange marmalade, or star fruit",
                    "requirements": [
                        {
                            "requirement_type": "time since last consumption",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Recent major surgery (within 6 weeks prior to the start of study treatment)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "diagnosis"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1) are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients with human immunodeficiency virus (HIV) ... are not eligible",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with ... human T-cell leukemia virus 1 (HTLV-1) are not eligible",
                    "criterion": "human T-cell leukemia virus 1 (HTLV-1) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any chemotherapy or radiation therapy within 4 weeks of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Any chemotherapy ... within 4 weeks of the first dose of study drug",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... radiation therapy within 4 weeks of the first dose of study drug",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection; patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing",
            "criterions": [
                {
                    "exact_snippets": "Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR)",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis C infection",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent",
                    "criterion": "hepatitis B core antibody positivity",
                    "requirements": [
                        {
                            "requirement_type": "prophylaxis with lamivudine or equivalent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are hepatitis B core antibody positive ... be willing to undergo monthly hepatitis B DNA PCR testing",
                    "criterion": "hepatitis B core antibody positivity",
                    "requirements": [
                        {
                            "requirement_type": "willingness for monthly hepatitis B DNA PCR testing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of venetoclax and lenalidomide, or put the study outcomes at undue risk",
            "criterions": [
                {
                    "exact_snippets": "Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety",
                    "criterion": "illness, medical condition or organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion: risk to subject's safety",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could ... interfere with the absorption or metabolism of venetoclax and lenalidomide",
                    "criterion": "illness, medical condition or organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion: interference with absorption or metabolism of venetoclax and lenalidomide",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could ... put the study outcomes at undue risk",
                    "criterion": "illness, medical condition or organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion: risk to study outcomes",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy",
            "criterions": [
                {
                    "exact_snippets": "Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal",
                                "mycobacterial",
                                "parasitic",
                                "other"
                            ]
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at study enrollment"
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "excluding fungal infections of nail beds"
                        }
                    ]
                },
                {
                    "exact_snippets": "any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy",
                    "criterion": "major episode of infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring treatment with IV antibiotics or hospitalization"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 4 weeks prior study therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of venetoclax or lenalidomide",
            "criterions": [
                {
                    "exact_snippets": "Unable to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "disease significantly affecting gastrointestinal function",
                    "criterion": "disease affecting gastrointestinal function",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "resection of the stomach or small bowel",
                    "criterion": "resection of the stomach or small bowel",
                    "requirements": [
                        {
                            "requirement_type": "history of resection",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic inflammatory bowel disease",
                    "criterion": "symptomatic inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of venetoclax or lenalidomide",
                    "criterion": "bowel obstruction interfering with drug delivery, absorption, or metabolism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other malignancy that could affect compliance with the protocol or interpretation of results; patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible; patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded; individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancy that could affect compliance with the protocol or interpretation of results",
                    "criterion": "history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible",
                    "criterion": "history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded",
                    "criterion": "malignancy treated with surgery alone with curative intent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator",
                    "criterion": "documented remission without treatment duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}